Latest Dihydroergotamine Stories

MOUNTAIN VIEW, Calif., April 12, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present new data from two safety studies of LEVADEX® orally inhaled migraine drug. The data will be presented at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Honolulu, Hawaii April 9-16, 2011. LEVADEX is an investigational acute drug for migraine that has completed Phase 3 clinical development. Findings to be presented at 2:00...

MOUNTAIN VIEW, Calif., Feb. 28, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that LEVADEX(TM) orally inhaled migraine therapy will be featured in one oral presentation and four poster presentations at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Honolulu, Hawaii April 9-16, 2011. A summary of the Company's AAN presentations is below, and the abstracts can be accessed at the AAN website at www.aan.com. LEVADEX is an investigational...

MOUNTAIN VIEW, Calif., Oct. 20 /PRNewswire-FirstCall/ --MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present nine analyses relating to its LEVADEX(TM) orally inhaled migraine therapy product candidate, including analysis from the FREEDOM-301 Phase 3 trial, at the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France. EHMTIC is a biennial congress of the Migraine Trust and the European Headache Federation for...

MOUNTAIN VIEW, Calif., Sept. 8 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today reported results from a pharmacodynamics (PD) trial comparing the acute effects on pulmonary artery pressure of LEVADEX(TM), dihydroergotamine mesylate (DHE) administered intravenously (IV) and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after...

MOUNTAIN VIEW, Calif., July 13 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced results from a clinical trial comparing the pharmacokinetics (PK) and safety of LEVADEX(TM) orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. The trial was designed to measure whether systemic absorption and exposure in smokers is greater than in non-smokers. In the trial, the systemic absorption of LEVADEX was not...

MOUNTAIN VIEW, Calif., May 11 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today provided an update on its development program for LEVADEX(TM) orally inhaled migraine therapy. LEVADEX has completed Phase 3 efficacy development for the acute treatment of migraine. "We continue to make good progress with our LEVADEX program," said Timothy S. Nelson, President and CEO of MAP Pharmaceuticals. "Recent clinical and CMC discussions with the FDA have provided us with clarity...

MOUNTAIN VIEW, Calif., April 7 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company initiated a pharmacodynamics (PD) trial to compare the acute effect of LEVADEX(TM) orally inhaled migraine therapy to intravenous dihydroergotamine mesylate (IV DHE) and placebo on pulmonary artery pressure as measured by echocardiography. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment...

MOUNTAIN VIEW, Calif., Feb. 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company initiated a trial to compare the pharmacokinetics (PK), safety and metabolic profiles of LEVADEX(TM) orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine. This PK trial is...

MOUNTAIN VIEW, Calif., Jan. 11 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The...

MOUNTAIN VIEW, Calif., Sept. 22 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced publication of results from an in vitro study of its novel LEVADEX(TM) (MAP0004) orally inhaled migraine therapy in development exploring the potential mechanism by which the pharmacokinetics (PK) and pharmacodynamics of LEVADEX may produce fewer adverse events than those seen with intravenous dihydroergotamine (DHE). Results will be published in a manuscript titled Reduced...